SWOG clinical trial number
S0518

Phase III Prospective Randomized Comparison of Depot Octreotide plus Interferon Alpha versus Depot Octreotide plus Bevacizumab (NSC #704865) in Advanced, Poor Prognosis Carcinoid Patients

100% Accrual
Accrual
100%
Closed
Phase
100% Accrual
Accrual
100%
Published
Abbreviated Title
CARCINOID Ph III depot octreotide + either interferon alpha or bevacizumab
Activated
12/01/2007
Closed
09/01/2012
Participants
NCORP, Members, Medical Oncologists, CTSU, Affiliates

Research committees

Gastrointestinal Cancer

Treatment

Interferon alpha-2b Bevacizumab Octreotide acetate for injectable suspension